Activation of the cholinergic anti-inflammatory system in peripheral blood mononuclear cells from patients with Borderline Personality Disorder

Journal of Psychiatric Research

Volumn 46, Issue 12, 2012, Pages 1610-1617

  Díaz Marsá, Marina ^a,b,c   MacDowell, Karina S ^a,b,d   Guemes, Itziar ^a,b,c   Rubio, Víctor ^a,b,c   Carrasco, José L ^a,b,c   Leza, Juan C ^a,b,d  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Biomarker; Borderline Personality Disorder; Cholinergic receptor; Inflammatory antiinflamamtory balance

Indexed keywords

BUNGAROTOXIN RECEPTOR; COTININE; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; NICOTINE; NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; BORDERLINE STATE; CASE CONTROL STUDY; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MENTAL PATIENT; NERVOUS SYSTEM INFLAMMATION; OXIDATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 84868148338     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.09.009     Document Type: Article

References (55)

1. American Psychiatric Association Diagnostic criteria from DSM-IV-TR 2000, American Psychiatric Association, Washington, D.C.
2. Benowitz N.L., Bernert J.T., Caraballo R.S., Holiday D.B., Wang J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. American Journal of Epidemiology 2009, 169(2):236-248.
3. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience & Biobehavioral Reviews 2011, 35(3):804-817.
4. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-238.
5. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., Petrov D., et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(4):1920-1925.
6. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976, 72:248-254.
8. Briggs C.A., McKenna D.G., Monteggia L.M., Touma E., Roch J.M., Arneric S.P., et al. Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant. European Journal of Pharmacology 1999, 366(2-3):301-308.
9. Campanucci V.A., Krishnaswamy A., Cooper E. Mitochondrial reactive oxygen species inactivate neuronal nicotinic acetylcholine receptors and induce long-term depression of fast nicotinic synaptic transmission. Journal of Neuroscience 2008, 28(7):1733-1744.
10. Carrasco J.L., Díaz-Marsá M., Pastrana J., Molina R., Brotons L., Horcajadas C. Enhanced suppression of cortisol after dexamethasone test in borderline personality disorder. A pilot study. Actas Españolas de Psiquiatría 2003, 31:138-141.
11. Chapman A.L., Leung D.W., Lynch T.R. Impulsivity and emotion dysregulation in borderline personality disorder. Journal of Personality Disorders 2008, 22:148-164.
12. Coccaro E.F., Lee R., McCloskey M. Norepinephrine function in personality disorder: plasma free MHPG correlates inversely with life history of aggression. CNS Spectrums 2003, 8(10):731-736.
13. Coccaro E.F., Lee R., Kavoussi R.J. Aggression, suicidality, and intermittent explosive disorder: serotonergic correlates in personality disorder and healthy control subjects. Neuropsychopharmacology 2010, 35(2):435-444.
14. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 2008, 9(1):46-56.
15. Fan X., Goff D.C., Henderson D.C. Inflammation and schizophrenia. Expert Review of Neurotherapeutics 2007, 7:789-796.
16. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, research version, non-patient edition (SCID-I/NP) 2002, Biometrics Research, New York State Psychiatric Institute, New York, NY.
17. First M.B., Spitzer R.L., Gibbon M., William J.B.W. Structured Clinical Interview for DSM-IV Axis II personality disorders (SCID-II) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
18. García-Bueno B., Caso J.R., Leza J.C. Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. Neuroscience & Biobehavioral Reviews 2008, 32(6):1136-1151.
19. García-Bueno B., Pérez-Nievas B.G., Leza J.C. Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases?. International Journal of Neuropsychopharmacology 2010, 13(10):1411-1429.
20. Grant B.F., Chou S.P., Goldstein R.B., Huang B., Stinson F.S., Saha T.D., et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 2008, 69:533-545.
21. Grossman R., Yehuda R., New A., Schmeidler J., Silverman J., Mitropoulou V., et al. Dexamethasone suppression test findings in subjects with personality disorders: associations with posttraumatic stress disorder and major depression. American Journal of Psychiatry 2003, 160:1291-1297.
22. Gurvits I.G., Koenigsberg H.W., Siever L.J. Neurotransmitter dysfunction in patients with borderline personality disorder. Psychiatric Clinics of North America 2000, 23:27-40.
23. Himmerich H., Milenović S., Fulda S., Plümäkers B., Sheldrick A.J., Michel T.M., et al. Regulatory T cells increased while IL-1β decreased during antidepressant therapy. Journal of Psychiatric Research 2010, 44:1052-1057.
24. Himmerich H., Schönherr J., Fulda S., Sheldrick A.J., Bauer K., Sack U. Impact of antipsychotics on cytokine production in-vitro. Journal of Psychiatric Research 2011, 45:1358-1365.
25. Hope S., Dieset I., Agartz I., Steen N.E., Ueland T., Melle I., et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. Journal of Psychiatric Research 2011, 45:1608-1616.
26. Jacob G.A., Gutz L., Bader K., Lieb K., Tüscher O., Stahl C. Impulsivity in borderline personality disorder: impairment in self-report measures, but not behavioral inhibition. Psychopathology 2010, 43:180-188.
27. Jones C.K., Byun N., Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2012, 37(1):16-42.
28. Kahl K.G., Bens S., Ziegler K., Rudolf S., Dibbelt L., Kordon A., et al. Cortisol, the cortisol-dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biological Psychiatry 2006, 59(7):667-671.
29. Korzekwa M.I., Dell P.F., Links P.S., Thabane L., Webb S.P. Estimating the prevalence of borderline personality disorder in psychiatric outpatients using a two-phase procedure. Comprehensive Psychiatry 2008, 49:380-386.
30. Lawrence K.A., Allen J.S., Chanen A.M. Impulsivity in borderline personality disorder: reward-based decision-making and its relationship to emotional distress. Journal of Personality Disorders 2010, 24:786-799.
31. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuroendocrinology Letters 2008, 29(3):287-291.
32. Maes M. An intriguing and hitherto unexplained co-occurrence: depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2011, 35(3):784-794. 29.
33. Maes M., Kubera M., Obuchowiczwa E., Goehler L., Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinology Letters 2011, 32(1):7-24.
34. Maes M., Mihaylova I., Kubera M., Leunis J.C., Twisk F.N., Geffard M. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. Journal of Affective Disorders 2011, 135(1-3):414-418.
35. Martinez-Gras I., Pérez-Nievas B.G., Garcia-Bueno B., Madrigal J.L., Andrés-Esteban E., Rodríguez-Jiménez R., et al. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophrenia Research 2011, 128(1-3):15-22.
36. Mercer D., Douglass A.B., Links P.S. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. Journal of Personality Disorders 2009, 23:156-174.
37. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behavior and Immunity 2011, 25(8):1507-1518.
38. Meyer U., Schwarz M.J., Muller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacology & Therapeutics 2011, 132(1):96-110.
39. Müller N., Schwarz M.J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. European Archives of Psychiatry and Clinical Neuroscience 2008, 258(Suppl. 2):97-106.
40. Nizri E., Irony-Tur-Sinai M., Lory O., Orr-Urtreger A., Lavi E., Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. Journal of Immunology 2009, 183(10):6681-6688.
41. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Archives of General Psychiatry 2005, 62(6):649-659.
42. Schreiber E., Matthias P., Müller M.M., Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Research 1989, 17:6419.
43. Schwarz E., Guest P.C., Rahmoune H., Martins-de-Souza D., Niebuhr D.W., Weber N.S., et al. Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. World Journal of Biological Psychiatry 2011 Sep 22, 10.3109/15622975.2011.599861.
44. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., et al. Identification of a biological signature for schizophrenia in serum. Molecular Psychiatry 2012, 17(5):494-502.
45. Sorrells S.F., Sapolsky R.M. An inflammatory review of glucocorticoid actions in the CNS. Brain Behavior and Immunity 2007, 21(3):259-272.
46. Sublette M.E., Galfalvy H.C., Fuchs D., Lapidus M., Grunebaum M.F., Oquendo M.A., et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behavior and Immunity 2011, 25(6):1272-1278.
47. Sutin A.R., Terracciano A., Deiana B., Naitza S., Ferrucci L., Uda M., et al. High neuroticism and low conscientiousness are associated with interleukin-6. Psychologie Medicale 2010, 40(9):1485-1493.
48. Tragesser S.L., Robinson R.J. The role of affective instability and UPPS impulsivity in borderline personality disorder features. Journal of Personality Disorders 2009, 23:370-383.
49. Tyrer P., Silk K.R. A comparison of UK and US guidelines for drug treatment in borderline personality disorder. International Review of Psychiatry 2011, 23:388-394.
50. Vogel F., Wagner S., Başkaya O., Leuenberger B., Mobascher A., Dahmen N., et al. Variable number of tandem repeat polymorphisms of the arginine vasopressin receptor 1A gene and impulsive aggression in patients with borderline personality disorder. Psychiatr Genet 2012, 22(2):105-106.
51. Wang H., Liao H., Ochani M., Justiniani M., Lin X., Yang L., et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
52. Wang H., Yu M., Ochani C.A., Amella C.A., Tanovic M., Susarla S., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Natural Medicines 2004, 10(11):1216-1221.
53. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011, 15(7):2011-2035.
54. Zanarini M.C., Frankenburg F.R., Reich D.B., Silk K.R., Hudson J.I., McSweeney L.B. The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. American Journal of Psychiatry 2007, 164:929-935.
55. Zimmerman D.J., Choi-Kain L.W. The hypothalamic-pituitary-adrenal axis in borderline personality disorder: a review. Harvard Review of Psychiatry 2009, 17(3):167-183.